Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) is a complex neurological disorder with variable clinical courses and treatment responses.
• Maintenance therapy is often necessary for CIDP due to its relapsing nature, but treatment consensus is lacking.
• Standard treatments may not be sufficient for all CIDP patients, necessitating exploration of alternative therapies.

Observation:

• A patient with refractory CIDP, initially treated with prednisolone and cyclophosphamide, required frequent plasma exchange and intravenous immunoglobulin (IVIg).
• Introduction of ciclosporin to the treatment regimen eliminated the need for repeated IVIg administrations in this patient.
• Subsequent analysis included 14 additional cases, with three demonstrating improvement with ciclosporin therapy.

Findings:

• Ciclosporin demonstrated efficacy in managing a patient with intractable CIDP, significantly reducing the reliance on repeated IVIg.
• The study presents a suggested treatment protocol algorithm for CIDP management.
• Ciclosporin appears to be a viable option for patients with CIDP who are refractory to standard treatments and require frequent IVIg.

Implications:

• Ciclosporin should be considered as a therapeutic option for patients with severe or intractable CIDP.
• This research may influence future treatment guidelines for CIDP management, particularly for cases requiring intensive therapy.
• Further investigation into ciclosporin's long-term efficacy and safety in CIDP is warranted.